Khatami Fatemeh, Tavangar Seyed Mohammad
1Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
2Departments of Pathology, Doctor Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Diabetes Metab Disord. 2018 Mar 26;17(1):19-30. doi: 10.1007/s40200-018-0334-x. eCollection 2018 Jun.
The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements.
肿瘤的异质性被认为是成功实现个性化癌症治疗的主要困难。对于体内肿瘤异质性及其相关的冲突机制，迫切需要进行一致的反应评估。在这种情况下，研究人员将能够跟上癌症管理中预测性、预防性、个性化和参与性（P4）医学的步伐。事实上，肿瘤异质性是癌症进化的核心部分，因此为了在理解肿瘤内动态变化方面取得进展，一些诊断设备应该得到改进。最新的分子技术，如下一代测序（NGS）和超深度测序，可以揭示液体肿瘤活检中的一些克隆，这些克隆主要导致治疗耐药性。循环肿瘤DNA（ctDNA）作为液体活检的主要成分，是一种用于癌症突变追踪和分析的优秀生物标志物。个性化医疗有助于了解肿瘤的基因库及其对治疗的可能反应，而使用ctDNA可以使这一过程变得更加容易。有了这些信息，临床医生期待着在精准医疗的道路上找到预防、筛查和治疗的最佳策略。目前，这种信息丰富的改良治疗方法的众多临床疗效正在掌握之中。在此，我们对血浆来源的ctDNA研究在个性化癌症管理中的应用进行综述。
